ClinicalTrials.gg
RecruitingNCT05093907Updated Mar 10, 2025

A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer

A Phase 1/2 interventional study of BEY1107 and Capecitabine in Metastatic Colorectal Cancer, sponsored by BeyondBio Inc.. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by BeyondBio Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 283 studies in Colorectal Neoplasms with a site in Korea, Republic of — 60 open to participants now, 95 under way, 13 of them phase 3. Colorectal Neoplasms · Korea, Republic of.

Planned enrollment
226th of 251
27 · median 150
Started
2021
with 29 others
Phase 1/2
42 of 283
12 open now
Primary completion
2026-11
later than 32 of 94 live
Registered
191st of 283
by date

Among the 283 studies in Colorectal Neoplasms with a site in Korea, Republic of, this one is the 226th largest by planned enrollment of the 251 interventional ones that give a count, is one of 30 that started in 2021, is one of 42 in phase 1/2, reaches primary completion later than 32 of the 94 other live ones, and was the 191st registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

60 of the 283 studies in Colorectal Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Colorectal Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a Phase 1/2 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with capecitabine in patients with metastatic colorectal cancer refractory or intolerant to standard of care (SoC).

Read the detailed description

In Phase 1, patients who experienced treatment failure of colorectal cancer with the second-line or beyond standard chemotherapy will be enrolled at each dose level of BEY1107 in combination with Capecitabine. Phase 2 will be conducted after RP2D is determined on the Phase 1 results.

03

Conditions studied

  • Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult males and females aged over 19 years or older at the time of .
  2. Histopathologically or diagnosed with colorectal cancer.
  3. Patients with unresectable lesion(s).
  4. Patients who experienced treatment failure of colorectal cancer with the or beyond standard chemotherapy (including fluoropyrimidine, oxaliplatin and irinotecan).
  5. Subjects who have at least one measurable or evaluable lesion as per v1.1.
  6. Subjects with performance status 0 or 1.
  7. Women of who are not surgically sterile must consent to practice acceptable until 6 months after the end of IP administration and also have the evidence of not being fertile.
  8. Non-vasectomized men who consent to use an acceptable contraception by one-self and the partner until 3 months after the end of IP administration.
  9. Patients who are fully informed of this trial, voluntarily decide to participate in the trial and provide written consent to comply with requirements for the trial.

Exclusion criteria

Exclusion Criteria:

  1. Patients who received radiation therapy, chemotherapy or biological agent including hormone therapy recently.
  2. Subjects who had a surgery with general anesthesia within 4 weeks of screening.
  3. Subjects with symptomatic .
  4. Subjects with peripheral neuropathy.
  5. Subjects who had findings of affecting absorptin of the IP with gastrointestinal surgery or impossible oral drug administration.
  6. Subjects with systemic disease not suitable for anticancer agent administration at the discretion of the investigator.
  7. Subjects who had a cardiovascular disease as of screening.
  8. Subjects with history of other than basal cell carcinoma of the skin or cervical carcinoma in situ or papillary thyroid cancer appropriately treated within 5 years.
  9. Gastrointestinal bleeding or ulcer.
  10. Dihydro-Pyridine Dehydrogenase (DPD) deficiency.
  11. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
  12. to the ingredient(s) of the product (BEY 1107) or capecitabine, 5-FU (fluorouracil).
  13. Positive.
  14. Ineligible result of , by the investigator.
  15. Acute or severe infection.
  16. Subjects who take a Sorivudine or brivudine in combination.
  17. Subjects who take a combination of tegafur, gimeracil and oteracil potassium or discontinue within 7 days at the screening.
  18. Subjects who take a Rifampin and azole class antifungal drugs in combination.
  19. Subjects who has labortory findings of inadequate bone marrow, kidney and liver function.
  20. Pregnant women, breastfeeding women, or positive findings on the pregnancy test at screening.
  21. Subjects with of less than 12 weeks by the investigator.
  22. Subjects who had been administered other IP within 4 weeks prior to screening.
  23. Subjects determined by the investigator to be ineligible for participation in this trial.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    BEY1107 + Capecitabine

    Administer BEY1107 in combination with Capecitabine, 3-weeks as 1 cycle.

    Drug: BEY1107 · Combination Product: Capecitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose(MTD) assessed by investigator following administration of BEY1107 in combination with Capecitabine

    MTD will be assessed based on adverse events(including DLT assessment), vital signs, 12-lead ECG, laboratory tests, etc.

    Time frame: From baseline up to disease progression, approximately 54 weeks

  2. Objective Response Rate(ORR)(Phase 2) assessed by investigator following administration of BEY1107 in combination with Capecitabine

    ORR defined as proportion of subjects with a overall response of CR or PR

    Time frame: From baseline up to disease progression, approximately 54 weeks

Secondary outcomes

  1. Pharmacokinetic(PK) of Maximum Serum Concentration (Cmax) of BEY1107 in combination with Capecitabine

    Plasma concentrations at each time point and PK parameters Cmax of BEY1107 will be assessed in the PK sampling cohort

    Time frame: From baseline up to 24 hour post-dose

  2. Pharmacokinetic of Time to Reach Maximum Serum Concentration (Tmax) of BEY1107 in combination with Capecitabine

    Plasma concentrations at each time point and PK parameters Tmax of BEY1107 will be assessed in the PK sampling cohort

    Time frame: From baseline up to 24 hour post-dose

  3. Pharmacokinetic of Area Under the Serum Concentration-Time Curve Up to Last Quantifiable Time (AUClast) of BEY1107 in combination with Capecitabine

    Plasma concentrations at each time point and PK parameters AUClast of BEY1107 will be assessed in the PK sampling cohort

    Time frame: From baseline up to 24 hour post-dose

  4. Progression-free survival(PFS) assessed by investigator following administration of BEY1107 in combination with Capecitabine

    PFS is defined as the time from the start of study treatment to the date of the first documentation of objective PD or death due to any cause, whichever is earlier

    Time frame: From baseline up to disease progression, approximately 24 months

  5. Disease control rate(DCR) assessed by investigator following administration of BEY1107 in combination with Capecitabine

    DCR is defined as the proportion of participants who achieved a confirmed best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD)

    Time frame: From baseline up to approximately 24 months

07

Study locations

1 of 1 sites recruiting
  • Seoul National University Hospial
    Seoul, Jongro-go 03080, Korea, Republic of
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Nov 2026, 62 months after the start.

Of 159 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 82. This study's planned 62 months is close to that.

Counting every sponsor, half of 261 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2021
First posted
Oct 26, 2021
StartActual
Aug 31, 2021
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05093907
Lead sponsor
BeyondBio Inc.
Responsible party
Sponsor
First posted
Oct 26, 2021
Start date
Aug 31, 2021
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 10, 2025

Study contacts

BeyondBio Inc.
Contact
clinicaltrials@beyondbio.co.kr
+82-42-716-0020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avotaciclib

Start the discussion